tetano
Editor, Senior Moderator
Eurosurveillance, Volume 21, Issue 38, 22 September 2016
Surveillance and outbreak report
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results
R Pebody [SUP]1[/SUP] , F Warburton [SUP]1[/SUP] , J Ellis [SUP]1[/SUP] , N Andrews [SUP]1[/SUP] , A Potts [SUP]2[/SUP] , S Cottrell [SUP]3[/SUP] , J Johnston [SUP]4[/SUP] , A Reynolds [SUP]2[/SUP] , R Gunson [SUP]5[/SUP] , C Thompson [SUP]1[/SUP] , M Galiano [SUP]1[/SUP] , C Robertson [SUP]6[/SUP] , R Byford [SUP]7[/SUP] , N Gallagher [SUP]4[/SUP] , M Sinnathamby [SUP]1[/SUP] , I Yonova [SUP]7[/SUP] [SUP]8[/SUP] , S Pathirannehelage [SUP]7[/SUP] , M Donati [SUP]1[/SUP] , C Moore [SUP]3[/SUP] , S de Lusignan [SUP]7[/SUP] [SUP]8[/SUP] , J McMenamin [SUP]2[/SUP] , M Zambon [SUP]1[/SUP]
+ Author affiliations
1. Public Health England, London, United Kingdom
2. Health Protection Scotland, Glasgow, United Kingdom
3. Public Health Wales, Cardiff, United Kingdom
4. Public Health Agency Northern Ireland, Belfast, United Kingdom
5. West of Scotland Specialist Virology Centre, Glasgow, United Kingdom
6. University of Strathclyde, Glasgow, United Kingdom
7. University of Surrey, Guildford, United Kingdom
8. Royal College of General Practitioners, London, United Kingdom
Correspondence: Richard Pebody (richard.pebody@phe.gov.uk)
Citation style for this article: Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, Johnston J, Reynolds A, Gunson R, Thompson C, Galiano M, Robertson C, Byford R, Gallagher N, Sinnathamby M, Yonova I, Pathirannehelage S, Donati M, Moore C, de Lusignan S, McMenamin J, Zambon M. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016;21(38)
ii=30348. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.38.30348
Received:15 July 2016; Accepted:30 August 2016
[h=4][/h]
The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season?s adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0?61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6?64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1?68.6) against influenza B. In 2?17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6?94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.
full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22592
Surveillance and outbreak report
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results
R Pebody [SUP]1[/SUP] , F Warburton [SUP]1[/SUP] , J Ellis [SUP]1[/SUP] , N Andrews [SUP]1[/SUP] , A Potts [SUP]2[/SUP] , S Cottrell [SUP]3[/SUP] , J Johnston [SUP]4[/SUP] , A Reynolds [SUP]2[/SUP] , R Gunson [SUP]5[/SUP] , C Thompson [SUP]1[/SUP] , M Galiano [SUP]1[/SUP] , C Robertson [SUP]6[/SUP] , R Byford [SUP]7[/SUP] , N Gallagher [SUP]4[/SUP] , M Sinnathamby [SUP]1[/SUP] , I Yonova [SUP]7[/SUP] [SUP]8[/SUP] , S Pathirannehelage [SUP]7[/SUP] , M Donati [SUP]1[/SUP] , C Moore [SUP]3[/SUP] , S de Lusignan [SUP]7[/SUP] [SUP]8[/SUP] , J McMenamin [SUP]2[/SUP] , M Zambon [SUP]1[/SUP]
+ Author affiliations
1. Public Health England, London, United Kingdom
2. Health Protection Scotland, Glasgow, United Kingdom
3. Public Health Wales, Cardiff, United Kingdom
4. Public Health Agency Northern Ireland, Belfast, United Kingdom
5. West of Scotland Specialist Virology Centre, Glasgow, United Kingdom
6. University of Strathclyde, Glasgow, United Kingdom
7. University of Surrey, Guildford, United Kingdom
8. Royal College of General Practitioners, London, United Kingdom
Correspondence: Richard Pebody (richard.pebody@phe.gov.uk)
Citation style for this article: Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, Johnston J, Reynolds A, Gunson R, Thompson C, Galiano M, Robertson C, Byford R, Gallagher N, Sinnathamby M, Yonova I, Pathirannehelage S, Donati M, Moore C, de Lusignan S, McMenamin J, Zambon M. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016;21(38)
ii=30348. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.38.30348Received:15 July 2016; Accepted:30 August 2016
[h=4][/h]
The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season?s adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0?61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6?64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1?68.6) against influenza B. In 2?17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6?94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.
full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22592